To my belief, since they focus on the far-east at first, the western countries doctors are less familiar with it. I assume the mexican grant will cause a change in the US (from patients asking doctors), and in Europe-the italian grant is relatively new, but will get more & more attention. These things takes time. Still, 20% quarterly growth is immense! I understand S&P companies present 6-7% annual growth, Nasdaq hi-techs: around 20% annualy. And this tiny SCLN presents a quarterly 20% ?! I'm not sure they could even handle a faster growth rate. I don't think Amgen was born in one day as well. These things take time.
I don't know chineese or any of those languages (french is enough) ;) so can't learn from far-east websites how much this drug is recognized there, but the sales speak pretty clear.
Now rethink on those classic majority of bio's, with poor to no sales at all, now suddenly getting the FDA, and are starting from scratch, with no marketing experience. These far-east sales should help SciClone US sales, when they're granted. It isn't an easy task to build a national marketing infrastructure, ask AMAZON...
The $13 as a wall? I recall having SCLN at 7-10 just not a long time ago (and the 10 was a barrier, even I noticed that), so can't deduce anything from a day or 2 - but I don't pretend to know about TA, for that this board has some really good posters, really, a great board. :) From the little I do know, I understand the increasing "low of the day" I noticed in SCLN is a good parameter. So be it. I'm not complaining. ;)
supergrit33: we're in the same stumble ship! :) I research the bio arena (I think every investor should have at least 1 bio stock in the coming decade), looked & read about various companies, going from one link to another, happened to tumble on SCLN, and "ahorka!" :)
Don Sellers the CEO lived in Hong Kong for a number of years. He understands how to market the product to the Asian medical community. This is the main reason I bought the stock in 97, Hep is a huge problem in Asia.
Hong Kong is now part of china, so this might explain that to be a main market for Zadaxin. Just wonder when SCLN will be traded in the Hong Kong market as well... (or maybe it already does?) This way you get trading: Hong Kong|Germany|US markets - SCLN 24 hours a day!